| 1.2 -0.05 (-4%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.5 | 1-year : | 1.75 |
| Resists | First : | 1.28 | Second : | 1.5 |
| Pivot price | 1.22 |
|||
| Supports | First : | 1.11 | Second : | 1 |
| MAs | MA(5) : | 1.25 |
MA(20) : | 1.19  |
| MA(100) : | 1.13 |
MA(250) : | 1.14 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 68.2 |
D(3) : | 81.6 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 1.79 | Low : | 0.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LUCD ] has closed above bottom band by 33.8%. Bollinger Bands are 45.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.25 - 1.26 | 1.26 - 1.26 |
| Low: | 1.17 - 1.18 | 1.18 - 1.19 |
| Close: | 1.19 - 1.2 | 1.2 - 1.21 |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Thu, 30 Oct 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025 - Eastern Progress
Wed, 29 Oct 2025
Lucid Diagnostics (NASDAQ: LUCD) to host webcast on Q3 2025 results update - Stock Titan
Sat, 25 Oct 2025
101,826,788 Common Stock of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 26-OCT-2025. - MarketScreener
Sat, 25 Oct 2025
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Thu, 16 Oct 2025
What Makes Lucid Diagnostics Inc. (LUCD) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Wed, 15 Oct 2025
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 102 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 33.6 (%) |
| Held by Institutions | 15 (%) |
| Shares Short | 3,680 (K) |
| Shares Short P.Month | 6,080 (K) |
| EPS | -0.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.47 |
| Profit Margin | 0 % |
| Operating Margin | -978.9 % |
| Return on Assets (ttm) | -82.4 % |
| Return on Equity (ttm) | -463.6 % |
| Qtrly Rev. Growth | 19.2 % |
| Gross Profit (p.s.) | -0.03 |
| Sales Per Share | 0.04 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -1.27 |
| PEG Ratio | 0 |
| Price to Book value | -2.61 |
| Price to Sales | 28.04 |
| Price to Cash Flow | -2.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|